ERBB2 and breast cancer: In the subgroup analysis of 19 TNBC and HER2+ breast cancer, CD3 still maintained its predictive value and the low expression of CD3 in the intratumoral primary lesions (P=0.015) and peritumoral oligometastatic lesions (P=0.040) had worse OS than did those with high expression (Figure 6).